Etrasimod improves clinical remission rates in patients with

1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission compared to placebo. 2. Majority of adverse events were mild-to-moderate in nature with no reported fatalities. Evidence Rating Level: 1 (Excellent) Study Rundown: Ulcerative colitis is a chronic, autoimmune disease of the gastrointestinal tract that

Related Keywords

, Rating Level , Maintenance Therapy , Between Jun , Crohn 039s Colitis , Crohn 039s Disease , Etrasimod , Gastroenterology , Inflammatory Bowel Disease Ibd , Sphingosine 1 Phosphate Receptor Modulator , Ulcerative Colitis , Chronic Disease , Rheumatology ,